NCT06088472View on ClinicalTrials.gov

TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 21, 2021

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Solid Tumors, Adult
Interventions
BIOLOGICAL

TIL injection

Autologous tumor infiltrating lymphocyte injection

Trial Locations (1)

221000

RECRUITING

The Affiliated Hospital of Xuzhou Medical University, Xuzhou

Sponsors

Lead Sponsor

Grit Biotechnology
All Listed Sponsors
collaborator

The Affiliated Hospital of Xuzhou Medical University

OTHER

lead

Grit Biotechnology

INDUSTRY

NCT06088472 - TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors | Biotech Hunter | Biotech Hunter